Domain Therapeutics, a clinical-stage biopharmaceutical company operating in France and Canada, focuses on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Backed by decades of research and validated by multiple pharma partnerships, the Company ensures rigorous GPCR target identification and selection as well as thorough analysis of tumor complexity and mechanisms to deliver the next generation of immunotherapies. Domain’s clinical-stage programs include M1069, an A2aR/A2b receptor antagonist identified during a research collaboration with Merck KGaA, DT-9081, its fully owned EP4 receptor antagonist and DT-9045 its PAR2 NAM antagonist, alongside a rich, optimized pipeline of first-in-class GPCR targets selected through Domain’s drug discovery platform. The Company raised €39m ($42m) in early 2022 to develop high-value drug candidates to address GPCR-mediated immunosuppression in immuno-oncology. Domain is backed by a syndicate of leading international venture capital funds from Europe, Asia and North America